Organon & Co. (NYSE: OGN) is an American pharmaceutical company headquartered in Jersey City, New Jersey, dedicated to improving women’s health worldwide. Spun off from Merck & Co. in June 2021, Organon operates a $6.2 billion business spanning women’s health, biosimilars, and established brands across more than 140 countries. Former Organon CEO Kevin Ali was the chief architect of the company, having spent over 30 years at Merck before leading the spinoff. Under his leadership, Organon grew its flagship product Nexplanon into a nearly $1 billion franchise and expanded through strategic acquisitions including Forendo Pharma and Alydia Health. Ali resigned in October 2025, and the company is now led by Interim CEO Joseph Morrissey.

(Suggested: Merck CEO Email & Net Worth – Robert Davis Salary)

Kevin Ali – Quick Facts

Organon Competitors

Organon & Co. operates in the competitive global pharmaceutical industry with a specialized focus on women’s health, biosimilars, and established brands. Key competitors of Organon include:

• Bayer AG – major women’s health and contraceptive portfolio
• Pfizer Inc. – broad pharmaceutical portfolio with women’s health products
• Viatris Inc. – established brands and biosimilars competitor
• Roche Holding AG – diagnostics and biopharmaceuticals
• Theramex – dedicated women’s health pharmaceutical company
• AbbVie Inc. – competes in women’s health and immunology
• Johnson & Johnson – broad healthcare portfolio
• Teva Pharmaceutical Industries – generics and biosimilars

Kevin Ali Net Worth 2026 – Organon CEO Salary

As of 2026, Kevin Ali’s net worth is estimated at approximately $20–30 million USD, based on his cumulative compensation during his tenure as Organon CEO from 2021 to 2025, including stock awards and equity holdings. It is important to note that Ali agreed to forego severance and equity-related retirement benefits as part of his resignation in October 2025, which may have reduced the value of his holdings.

Organon CEO Compensation Breakdown (FY2024)

Organon Net Worth 2026 – Is Organon Profitable?

Yes, Organon & Co. is a profitable company. For the full year 2025, Organon reported revenue of $6.2 billion and net income of $187 million. The company generated adjusted EBITDA of $1.91 billion with a 30.7% margin. However, revenue declined 3% year-over-year, and net income dropped significantly from $864 million in FY2024 due to higher manufacturing optimization costs, Nexplanon access restrictions, and the leadership disruption. The company’s market capitalization stood at approximately $2.2 billion as of early 2026.

Organon Financial Summary (FY2025)

(Recommended: Pfizer CEO Email & Net Worth – Albert Bourla Salary)

Organon CEO Email Address | Kevin Ali Contact

Below are the contact details and social media profiles associated with former Organon CEO Kevin Ali. Note that since Ali resigned in October 2025, his corporate email may no longer be active. For current Organon inquiries, contact the company directly.

Career & Education – Company, University, & College

Kevin Ali is a veteran pharmaceutical executive with over three decades of global healthcare experience. He spent the majority of his career at Merck & Co. (known as MSD outside the United States), rising from a sales representative to leading all international operations. He was handpicked by then-Merck CEO Kenneth Frazier to architect the Organon spinoff — the largest women’s health company in the world at its launch.

Kevin Ali Career Timeline

Ali began his pharmaceutical career at Merck & Co. in the late 1980s as a sales representative. Over six years in sales, he gained a deep understanding of the industry before transitioning into international leadership roles. He spent more than 20 years living and working overseas — first in Egypt as Marketing Director, then as Business Unit Director in Germany, and later as Managing Director for Turkey (the first American to run that subsidiary) and Germany.

By 2011, Ali had risen to Senior Vice President overseeing multiple therapeutic areas including bone, respiratory, dermatology, and immunology. He then established Merck’s emerging markets business, serving as President for approximately six years. In 2017, he was appointed President of MSD International, with commercial responsibility for all markets outside the United States — representing 96% of the world’s population and over half of Merck’s pharmaceutical revenues.

(Related: Zoetis CEO Email & Net Worth – Kristin Peck Salary)

In 2019, Merck CEO Kenneth Frazier personally challenged Ali to create a new standalone women’s health company. Ali led the spinoff effort, and on June 3, 2021, Organon & Co. was officially launched as an independent publicly traded company on the NYSE. Ali served as CEO from inception until his resignation on October 26, 2025.

Education

Kevin Ali Wiki – Age, Family, & More

Kevin Ali (age 63 as of 2026) is based in the New Jersey area. He lives with his wife Hanaa, and the couple has two children. Ali is known for his deep personal commitment to advancing women’s health globally — a cause that drove his decision to leave a three-decade career at Merck to build Organon from the ground up.

Notable Achievements & Recognitions

• Architect of Organon – Led the creation and spinoff of the world’s largest women’s health pharmaceutical company from Merck & Co.
• 30+ Year Merck Veteran – Rose from sales representative to President of MSD International, leading operations across 140+ countries
• U.S. Chamber of Commerce – Served as Chair of the China Center Advisory Board
• World Economic Forum – Active participant and speaker at Davos on women’s health and pharmaceutical innovation
• Global Healthcare Advocate – Champion of expanding women’s healthcare access in emerging markets worldwide
• First American MD in Merck Turkey & Germany – Pioneered international leadership roles at Merck

Ali believes that women’s healthcare is not merely a profitable market sector but a fundamental obligation to the betterment of women worldwide. He has consistently advocated for listening to patients’ perspectives and building healthcare solutions that address underserved needs.

(Suggested: West Pharma CEO Email & Net Worth – Eric Green Salary)

About Organon & Co.

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Spun off from Merck & Co. on June 3, 2021, the company is dedicated to delivering impactful medicines and solutions for women’s health and beyond. Organon operates across three main business segments:

Organon trades on the New York Stock Exchange under the ticker symbol OGN. The company employs approximately 10,000 people and markets products in more than 140 countries. Its mission is centered on delivering impactful medicines and solutions in women’s health, biosimilars, and established brands to serve patients globally.

Frequently Asked Questions (FAQ)

Who is the current CEO of Organon?

As of February 2026, Joseph Morrissey is serving as Interim CEO of Organon & Co. The previous CEO, Kevin Ali, resigned on October 26, 2025 following an internal investigation into improper Nexplanon sales practices. The Board of Directors is conducting a search for a permanent CEO, considering both internal and external candidates.

What is Kevin Ali’s net worth in 2026?

Kevin Ali’s net worth is estimated at approximately $20–30 million USD as of 2026, based on cumulative compensation and equity holdings during his four-year tenure as Organon CEO. However, Ali agreed to forego severance and equity-related retirement benefits upon his resignation, which may have reduced the total value.

What was Organon CEO Kevin Ali’s salary?

For fiscal year 2024, Kevin Ali’s total compensation was approximately $17.1 million, which included a $1.25 million base salary, $2.51 million annual bonus, $2.75 million in stock options, $9.16 million in stock awards (RSUs/PSUs), and $1.44 million in other compensation. Approximately 70% of his pay was equity-based.

What is Organon CEO’s email address?

Kevin Ali’s email at Organon was [email protected], though this address may no longer be active following his October 2025 departure. For general inquiries, contact Organon at 551-430-6000 or email [email protected] for press inquiries. Kevin Ali can also be reached via LinkedIn.

Why did Kevin Ali resign from Organon?

Kevin Ali resigned from Organon on October 26, 2025 after the company’s audit committee investigation found that Organon had asked certain U.S. wholesalers to purchase more Nexplanon (a contraceptive implant) than needed, across multiple quarters in 2022, 2024, and 2025. The company encouraged those purchases by providing “incentive fees” linked to inventory management metrics. Ali agreed to forego severance and equity-related retirement benefits.

Is Organon a profitable company?

Yes, Organon remains profitable. In full-year 2025, the company posted net income of $187 million on revenue of $6.2 billion, though this was a significant decline from $864 million in net income in FY2024. The adjusted EBITDA was $1.91 billion with a 30.7% margin. For 2026, management projects approximately flat revenue and EBITDA.

Article last updated:January 2026March 2, 2026